In particular, the reclassification of this novel variant allows the patient to be treated with PARP-inhibitors, since only pathogenic/likely pathogenic variants grant access to this therapy, which, thanks to the Olympia study (25), is now offered to patients with HER2 negative breast cancers, especially in the metastatic stage. This evidence concerns the gene ERBB2 and breast carcinoma.